{
  "figure_0010": "",
  "figure_0001": "SLC31A1 is associated with breast cancer progression. (A) DEGs for the normal, paired primary and recurrent breast cancer tissues (n = 6 per group). (B) IF staining for SLC31A1 in tissues from our breast cancer cohort (n = 6 per group). Scale bar, 50 μm. (C) Quantification for SLC31A1 fluorescent intensity was shown. (D) The expression of SLC31A1 was elevated in breast cancer tissues compared to normal tissues based on TCGA database. (E,F) Kaplan-Meier plotter analysis showing that high SLC31A1 expression levels predict poor overall survival rate (OS) and progress free interval (PFI) in breast cancer patients based on TCGA dataset. (G) IHC staining results for SLC31A1 in patients with breast cancer from HPA database (https://www.proteinatlas.org/). Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.",
  "figure_0002": "SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients. (A) Expression of SLC31A1 in varying tumor tissues and normal tissues from the TIMER database (https://cistrome.shinyapps.io/timer/). (B) Correlation between SLC31A1 gene expression and the expression of ESR1 (ERα), ESR2 (ERβ), ERBB2 (HER2) and PGR in BRCA-basal patients (n = 139) in TIMER. (C) Correlation between SLC31A1 gene expression and the expression of ESR1, ESR2, ERBB2 and PGR in breast invasive carcinoma (n = 1093) in TIMER. (D) Correlation between SLC31A1 gene expression and the expression of ESR1 and ESR2 in BRCA-luminal samples (n = 611) in TIMER. (E) Correlation between SLC31A1 gene expression and the expression of ERBB2 in BRCA-HER2 samples (n = 67) in TIMER. (F) RT-qPCR, (G) western blot and (H) IF staining assays for SLC31A1 mRNA and protein expression calculation in ER-positive (T47D, MCF7, BT474 and ZR-75-1) and -negative (MB231, MCF10A, HCC1954 and MB453) breast cancer cell lines (n = 3 in each group). Scale bar, 15 μm. SLCA31A, red; ER, green. Data were presented as means ± SD. *P<0.05, ⁎⁎P<0.01, ⁎⁎⁎P<0.001.",
  "figure_0003": "SLC31A1 is associated with tumor recurrence in ER-positive breast cancer. (A,B) RT-qPCR analysis for SLC31A1 in tumor tissues from ER-positive breast cancer patients and the paired normal tissues from our cohort (n = 85 in each group). (C) RT-qPCR analysis for SLC31A1 mRNA expression levels in tumor tissues from ER-positive breast cancer patients received tamoxifen treatments with (n = 18) or without recurrence (n = 67). (D) IHC staining for SLC31A1 in tumor tissues from ER-positive breast cancer patients received tamoxifen treatments with (n = 6) or without recurrence (n = 6). Scale bar, 50 μm. (E,F) IF staining images of SLC31A1 and Cytokeratin in ER-positive breast cancer tissues obtained pre- and post-chemotherapy responders without recurrence (n = 6), and SLC31A1 positive fluorescent intensity was quantified. Scale bar, 50 μm. (G,H) IF staining images of SLC31A1 and Cytokeratin in ER-positive breast cancer tissues obtained from pre- and post-chemotherapy with recurrence (n = 6), and SLC31A1 positive fluorescent intensity was quantified. Scale bar, 50 μm. (I,J) IF staining images of SLC31A1 and Cytokeratin in primary ER-positive breast cancer tissues and metastatic tumor tissues (n = 6), and SLC31A1 positive expression fluorescence was quantified. Scale bar, 50 μm. Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.",
  "figure_0004": "SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells. (A) CCK-8 analysis of T47D, MCF7, T47D/TR and MCF7/TR cells treated with varying concentrations of tamoxifen ranging from 0 to 20 μM for 24 h to examine the proliferation of tumor cells (n = 4 in each group). (B) RT-qPCR, (C) western blot and (D) IF staining assays for SLC31A1 mRNA and protein expression levels in parental T47D and MCF7 cells and TAM-resistant T47D (T47D/TR) and MCF7 (MCF7/TR) cell lines (n = 3 or 4 in each group). Scale bar, 15 μm. (E) RT-qPCR and (F) western blot analysis for SLC31A1 mRNA and protein expression levels in T47D, MCF7, T47D/TR and MCF7/TR cells with stable knockdown of SLC31A1 (n = 3 or 4 in each group). (G-I) T47D, MCF7, T47D/TR and MCF7/TR cells with or without SLC31A1 knockdown were exposed to TAM (2.5 μM) incubation for 24 h. Then, all cells were collected for subsequent assays. (G) Cell viability was assessed using CCK-8 analysis (n = 4 in each group). (H) EdU staining was used to calculate the cell proliferative capacity (n = 4 in each group). Scale bar, 50 μm. (I) Transwell analysis was conducted to examine the invasion of chemoresistant breast cancer cell lines (n = 4 in each group). Scale bar, 100 μm. Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.",
  "figure_0005": "SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro. (A) RT-qPCR and (B) western blot analysis for SLC31A1 mRNA and protein expression levels in T47D and MCF7 cells transfected with SLC31A1 over-expression plasmids (n = 3 or 4 in each group). (C) T47D and MCF7 cells with or without SLC31A1 over-expression were subjected to increasing concentrations of TAM incubation for 24 h, followed by CCK-8 analysis to evaluate the cell proliferation (n = 4 in each group). (D-F) T47D and MCF7 cells post SLC31A1 over-expression plasmids transfection were incubated with or without TAM (2.5 μM) for 24 h. Subsequently, all cells were collected for studies as follows. (D) Cell proliferation was examined using EdU staining (n = 4 in each group). Scale bar, 50 μm. (E) The number of invasive cells was quantified using transwell assay (n = 4 in each group). Scale bar, 100 μm. (F) RT-qPCR analysis for invasion markers including N-Cadherin, VEGF and MMP9 in cells (n = 4 in each group). Data were presented as means ± SD. *P<0.05, ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.",
  "figure_0006": "SLC31A1 mediates CPT1A-associated FAO in ER-positive breast cancer cells. (A) Copper concentrations in T47D, MCF7, T47D/TR and MCF7/TR cells with or without SLC31A1 knockdown (n = 4 in each group). (B) Volcano plot of DEGs in T47D/TR cells with SLC31A1 deletion versus the control group (n = 4 in each). Genes with p value <0.05 and gene fold change ≥1.5 were marked in purple (down-regulated) and orange (up-regulated) with genes not meeting the cut-off shown in gray. (C) KEGG enrichment scatter plot for DEGs genes in shSLC31A1 T47D/TR cells compared with the control group. (D) GSEA enrichment of the signaling pathways for breast cancer- and FAO-related genes. (E) Heatmap showing the FAO-associated gene expression levels by RT-qPCR analysis from T47D/TR cells with or without SLC31A1 knockdown (n = 3 in each). (F) RT-qPCR and (G) western blot analysis for CPT1A mRNA and protein expression levels in T47D, MCF7, T47D/TR and MCF7/TR cells as shown (n = 3 or 4 in each group). (H) FAO rates were measured in T47D, MCF7, T47D/TR and MCF7/TR cells (n = 4 in each group). (I) ATP levels in T47D, MCF7, T47D/TR and MCF7/TR cells were examined (n = 4 in each group). (J) Cell viability was examined in T47D/TR and MCF7/TR cells with CPT1A silence after varying concentrations of TAM incubation for 24 h (n = 4 per group). (K) BODIPY493/503 staining of T47D/TR and MCF7/TR cells with or without CPT1A deletion after PO stimulation (200 μM) for 24 h (n = 4 per group). Scale bar, 15 μm. (L) Representative images for MitoTracker (green) and actin (red) of T47D/TR and MCF7/TR cells with or without siCPT1A transfection after PO exposure (200 μM) for 24 h. Relative MitoTracker fluorescence was quantified (n = 4 per group). Scale bar, 15 μm. Data were presented as means ± SD. *P<0.05, ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.",
  "figure_0008": "SLC31A1 promotes FAO by regulating CPT1A in breast cancer cells. (A) Western blot analysis of CPT1A protein expression levels in T47D and MCF7 cells over-expressing SLC31A1 (n = 3 in each group). (B) Copper concentrations, (C) FAO rates and (D) ATP levels were examined in T47D and MCF7 cells transfected with oe-SLC31A1 or oe-Vec plasmids (n = 3 in each group). (E-L) T47D and MCF7 cells were transfected with oe-SLC31A1 and/or si-CPT1A in the presence or absence of ETO (10 μM) for 24 h. Then, all cells were collected for subsequent assays. (E) Cell viability was determined using CCK-8 analysis (n = 4 in each group). (F,G) EdU staining of T47D and MCF7 cells to assess cell proliferation (n = 4 in each group). Scale bar, 50 μm. (H,I) Invasive status of breast cancer cells was examined by transwell assay (n=4 in each group). Scale bar, 100 μm. (J) FAO rates and (K) ATP levels were examined (n=4 in each group). (L) CPT1A protein expression levels were measured by western blot analysis (n = 3 in each group). Data were presented as means ± SD. 7⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.",
  "figure_0009": "SLC31A1 knockdown improves ER-positive breast cancer cells to tamoxifen treatment in vivo. (A) Tumor samples collected from each group were imaged (n = 4 per group). (B) Tumor growth rates were measured (n = 4 per group). (C) Tumor weights were recorded (n = 4 per group). (D) H&E staining, and IHC staining of KI-67, CPT1A and N-Cadherin expression levels in tumor sections were performed (n = 4 per group). Scale bar, 50 μm. (E) Quantification for KI-67, CPT1A and N-Cadherin positive staining was exhibited. (F) IF staining for cleaved Caspase-3 in tumor sections (n = 4 per group). Scale bar, 50 μm. (G) Working model indicating the effects of SLC31A1 on chemoresistance in ER-positive breast cancer by inducing CPT1A-mediated FAO process. Data were presented as means ± SD. *P<0.05, ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001."
}